Speaker illustration

Professor Alfred Cheung

Salt Lake City ()

Empagliflozin decreases risk of kidney function decline in type 2 diabetes: slope analyses in patients with and without heart failure at baseline from the EMPA-REG OUTCOME trial.

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Miscellaneous

Session: Late Breaking Trials II: Focus on chronic heart failure

Thumbnail

This platform is supported by

logo Novo Nordisk